treosulfan has been researched along with Graft-Versus-Host Disease in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (18.52) | 29.6817 |
| 2010's | 24 (44.44) | 24.3611 |
| 2020's | 20 (37.04) | 2.80 |
| Authors | Studies |
|---|---|
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Berghuis, D; Bredius, RGM; Buddingh, EP; Guchelaar, HJ; Lankester, AC; Mohseny, AB; Smiers, FJW; van der Stoep, MYEC; Zwaveling, J | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Choi, ES; Im, HJ; Kang, SH; Kim, H; Koh, KN; Suh, JK | 1 |
| Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M | 1 |
| Basara, N; Baumgart, J; Beelen, DW; Benedetti, F; Bethge, W; Bieniaszewska, M; Casper, J; Ciceri, F; Dreger, P; Finke, J; Glass, B; Grigoleit, GU; Hilgendorf, I; Holler, E; Junghanß, C; Klein, A; La Rocca, U; Labussiere-Wallet, H; Markiewicz, M; Niederwieser, D; Patriarca, F; Pichlmeier, U; Rambaldi, A; Reményi, P; Russo, D; Schaefer-Eckart, K; Scheid, C; Socié, G; Stelljes, M; Stölzel, F; Stuhler, G; Verbeek, M; Wagner-Drouet, EM; Wulf, G | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Halder, R; Kapoor, J; Mehta, P; Singh, A; Singh, R; Verma, M; Yadav, N | 1 |
| Bueno, D; Casado-Abad, G; Martínez, AP; Mozo, Y; Olivas-Mazón, R; Sisinni, L | 1 |
| Arranto, C; Dalla Via, V; Heim, D; Junker, T; Matteazzi, F; Medinger, M; Passweg, JR; Recher, M; Stelmes, A; van den Berg, J | 1 |
| Balashov, D; Idarmacheva, A; Kobyzeva, D; Laberko, A; Maschan, A; Maschan, M; Nechesnyuk, A; Shcherbina, A; Shelikhova, L; Skvortsova, Y; Sultanova, E | 1 |
| Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M | 1 |
| Akcan, M; Aksoylar, S; Bax, B; Bulut, FD; Canda, E; Cartı, O; Çoker, M; Erdem, F; Kansoy, S; Oymak, Y; Ozek, G; Siviş, ZO; Uçar, SK; Yazıcı, H; Yoldaş Çelik, M | 1 |
| Adam, E; Bielorai, B; Hutt, D; Jacoby, E; Malkiel, S; Somech, R; Toren, A | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
| Gao, P; Guo, J; Han, D; Wu, W; Xue, N; Yang, H | 1 |
| Aksoy, BA; Aydoğdu, S; Bozkurt, C; Çipe, F; Dikme, G; Erdem, M; Ersoy, GZ; Fışgın, T; Hashemi, N; Murat, K; Öner, ÖB | 1 |
| Beléndez, C; Benítez, I; Bueno, D; Díaz de Heredia, C; Echecopar, C; Estival, P; Fernández Navarro, JM; Fuentes, C; Fuster, JL; Galán, V; González-Vicent, M; Margarit, A; Molina, B; Olivas, R; Palomo, P; Pascual, A; Pérez-Martínez, A; Plaza, M; Regueiro, A; Rifón, J; Ruz, B; Sissini, L; Urtasun, A | 1 |
| Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V | 1 |
| Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E | 1 |
| Albert, MH; Bader, P; Beier, R; Burkhardt, B; Chada, M; Ehl, S; Greil, J; Gruhn, B; Janka, G; Kühl, JS; Lang, P; Lehmberg, K; Meisel, R; Müller, I; Ozga, AK; Schlegel, PG; Schulz, A; Seidel, M; Speckmann, C; Sykora, KW; Wawer, A; Wössmann, W; Wustrau, K | 1 |
| Appelbaum, FR; Baumgart, J; Dahlberg, A; Deeg, HJ; Delaney, C; Gutman, JA; Milano, F; Nemecek, ER; Salit, RB; Summers, C; Thur, L | 1 |
| Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A | 1 |
| Altun, D; Doğu, EF; Haskoloğlu, Ş; İkincioğulları, A; İslamoğlu, C; Kendirli, T; Köstel Bal, S | 1 |
| Amit, O; Avivi, I; Chemnitz, JM; Hallek, M; Holtick, U; Moshe, Y; Ram, R; Scheid, C; Wolf, D | 1 |
| Abraham, A; Ahmed, R; Ganapule, A; George, B; Lakshmi, KM; Mathews, V; Sindhuvi, E; Srivastava, A; Viswabandya, A | 1 |
| Albert, MH; Beier, R; Beutel, K; Gruhn, B; Janka, G; Kröger, N; Lehmberg, K; Meisel, R; Müller, I; Schulz, A; Stachel, D; Woessmann, W | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Bouazzaoui, A; Dickhöfer, S; Holler, E; Huber, E; Kreuz, M; Wolff, D | 1 |
| Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M | 1 |
| Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C | 1 |
| Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE | 1 |
| Boztug, H; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Comoli, P; Giorgiani, G; Giraldi, E; Locatelli, F; Merli, P; Mina, T; Regazzi, M; Strocchio, L; Vinti, L; Zecca, M | 1 |
| Arnold, R; Ayuk, F; Beelen, D; Bethge, W; Bornhäuser, M; Gökbuget, N; Heinzelmann, M; Hölzer, D; Kobbe, G; Kröger, N; Martin, H; Meyer, RG; Pichlmeier, U; Schmid, C; Stelljes, M; Trenschel, R; Wolschke, C; Zander, A | 1 |
| Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M | 1 |
| Baidildina, D; Balashov, D; Bobrynina, V; Boyakova, E; Glushkova, S; Ilushina, M; Kalinina, V; Kazachenok, A; Kurnikova, E; Laberko, A; Maschan, A; Maschan, M; Muzalevskii, Y; Novichkova, G; Olshanskaya, Y; Persiantseva, M; Shelikhova, L; Skvortsova, Y | 1 |
| Beier, R; Bernardo, ME; Burroughs, L; Ewins, AM; Fraser, C; Gennery, AR; Gibson, B; Kalwak, K; Krol, L; Meyts, I; Morillo-Gutierrez, B; Müller, I; Rao, K; Schulz, A; Sedlacek, P; Slatter, M; Strahm, B; Sykora, KW; Talano, JA; Veys, P; Wachowiak, J; Woolfrey, A; Zaidman, I | 1 |
| Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S | 1 |
| Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M | 1 |
| Abinun, M; Amrolia, P; Cant, A; Davies, G; Flood, T; Gaspar, HB; Gennery, AR; Goulden, N; Hambleton, S; Nademi, Z; Qasim, W; Rao, K; Slatter, MA; Veys, P | 1 |
| Danylesko, I; Nagler, A; Shimoni, A | 1 |
| Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR | 1 |
| Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M | 1 |
| Astwood, E; Corker, E; Vora, A; Williams, J | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Baumgart, J; Down, JD; Etienne, K; Johnson, KW; Ploemacher, RE; Rombouts, EJ; Westerhof, GR; White-Scharf, ME | 1 |
| Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D | 1 |
| Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A | 1 |
| Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L | 1 |
| Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E | 1 |
| Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Seweryn, M; Wojnar, J; Wylezoł, I | 1 |
| Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J | 1 |
2 review(s) available for treosulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning | 2023 |
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
15 trial(s) available for treosulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study.
Topics: Busulfan; Fetal Blood; Graft vs Host Disease; Humans; Middle Aged; Prospective Studies | 2020 |
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine | 2018 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2015 |
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2014 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Transplantation Conditioning | 2015 |
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Topics: Acute Disease; Adolescent; Adult; Allografts; Blood Platelets; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neutrophils; Survival Rate; Transplantation Conditioning | 2016 |
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2008 |
37 other study(ies) available for treosulfan and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Data Mining; Electronic Health Records; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myalgia; Pain Measurement; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine | 2022 |
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Intercellular Signaling Peptides and Proteins; Retrospective Studies; Thalassemia; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2022 |
A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning | 2022 |
Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.
Topics: Adult; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Immunodeficiency Diseases | 2022 |
Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning | 2023 |
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2023 |
Hematopoietic stem cell transplantation with reduced toxicity conditioning regimen in mitochondrial neurogastrointestinal encephalopathy syndrome.
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous | 2023 |
Improved Outcome Following Busulfan-Based Conditioning in Children with Functional Neutrophil Disorders Undergoing Hematopoietic Stem Cell Transplant from HLA-Matched Donors.
Topics: Busulfan; Child; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Neutrophils; Transplantation Conditioning | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
The impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial?
Topics: Busulfan; Child; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning | 2023 |
Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Topics: Adolescent; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Retrospective Studies; Transplantation Conditioning | 2023 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2019 |
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Chimerism; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous | 2020 |
Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Male; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 2018 |
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.
Topics: Adolescent; Adult; Aged; Busulfan; Female; Germany; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Israel; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Probability; Prognosis; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2019 |
Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.
Topics: Adolescent; beta-Thalassemia; Bone Marrow Cells; Busulfan; Cause of Death; Child; Child, Preschool; Chimerism; Demography; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility Testing; Humans; Male; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Retrospective Studies; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Virus Diseases; Young Adult | 2014 |
Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution.
Topics: Animals; B-Lymphocytes; Bone Marrow Transplantation; Busulfan; Cytostatic Agents; Female; Gastrointestinal Diseases; Graft vs Host Disease; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Transplantation Conditioning; Whole-Body Irradiation | 2014 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vomiting | 2015 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2015 |
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.
Topics: Adolescent; Antigens, CD19; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Receptors, Antigen, T-Cell, alpha-beta; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Young Adult | 2016 |
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Chimerism; Cohort Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Survival Analysis; Transplantation Conditioning; United Kingdom | 2011 |
Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cells; Male; Mice; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning | 2004 |
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Treosulfan, cyclophosphamide and antithymocyte globulin for allogeneic hematopoietic cell transplantation in acquired severe aplastic anemia.
Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Retrospective Studies; Severity of Illness Index; Time Factors; Transplantation, Homologous | 2006 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |